First patient receives personalized cancer vaccine in NEOVACC Phase I trial
myNEO Therapeutics is proud to announce an important milestone in the NEOVACC Phase I clinical trial, with the first patient receiving a personalized therapeutic cancer vaccine for non-small cell lung cancer (NSCLC).
Led by The Clatterbridge Cancer Centre and the University of Liverpool, the NEOVACC study brings together academic institutions, healthcare providers, industry partners, regulatory agencies and government organizations to advance the development of personalized cancer immunotherapies.
As a technology partner in the consortium, myNEO Therapeutics contributes its proprietary ImmunoEngine platform for the discovery and prioritization of patient-specific neoantigens. These neoantigens form the foundation of each individualized therapeutic vaccine, enabling the translation of tumor sequencing data into personalized immunotherapy targets.
The dosing of the first patient represents a significant milestone for both the NEOVACC program and the broader field of personalized cancer vaccines. It demonstrates the successful clinical translation of advanced computational neoantigen discovery and brings the field another step closer to delivering more precise treatment options for patients with lung cancer.
We congratulate all researchers, clinicians, NHS teams and consortium partners whose dedication made this milestone possible. Above all, we sincerely thank the patients whose participation continues to advance cancer research and the future of precision immunotherapy.
About NEOVACC
NEOVACC is a Phase I clinical trial evaluating a personalized therapeutic cancer vaccine for patients with non-small cell lung cancer (NSCLC). The study combines advanced tumor sequencing, computational neoantigen discovery and individualized vaccine manufacturing to develop patient-specific immunotherapies.
The patient's story is covered by BBC and other news outlets:
https://www.bbc.com/news/articles/cvgl4925w0qo
https://news.liverpool.ac.uk/2026/07/30/world-first-as-patient-receives-pioneering-lung-cancer-vaccine/